Epitalon is part of the July 2026 FDA peptide discussion queue.
Evidence level: Primary regulatory
Sources: U.S. Food and Drug Administration
Use the regulatory record as the anchor for the initial page.
Research peptide
Epitalon
Epitalon is often discussed in longevity-oriented peptide content. The page starts as a regulatory watch entry and should be expanded only after source review.
Regulatory watch
Last reviewed 2026-06-30
Next review 2026-07-24
Evidence snapshot
Treat longevity claims as high-review claims that need precise sourcing and conservative wording.
Scheduled for FDA advisory committee discussion in July 2026.
Longevity-related content is especially prone to claim inflation.
Needs a post-meeting update before expansion.
Tracked claims
Sources on this page
Source records are stored in the repo and linked from each claim.
July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting
FDA advisory committee meeting notice listing multiple peptide bulk substances scheduled for discussion.
Certain bulk drug substances for use in compounding may present significant safety risks
FDA page summarizing bulk drug substances that may present significant safety risks in compounding contexts.
Related compounds
BPC-157
BPC-157 is widely discussed online in injury recovery and performance communities, but the public evidence and regulator...
Regulatory watchDSIP
DSIP appears in online sleep and recovery discussions. This page tracks the topic as a source-backed index entry pending...
Regulatory watchKPV
KPV is a peptide topic appearing in online wellness and research discussions. This page tracks the public source record ...
Regulatory watchSemax
Semax is often discussed online in cognitive and performance contexts. The index treats it as a source-backed watch item...
Regulatory watch